Bispecific GPC3/PD‑1 CAR‑T cells for the treatment of HCC
International Journal of Oncology · 10.03.2023 · 62 (4)
DOI: 10.3892/ijo.2023.5501 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Oncology, online erschienen am 10.03.2023. Verfasst von Dezhi Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Intervention and Cell Therapy Center, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, P.R. China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 51-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Intervention and Cell Therapy Center, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, P.R. China.
- Department of Scientific and Research, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, P.R. China.
- Department of Infectious Disease, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, P.R. China.
Zitieren
APA
Li, D., Qin, J., Zhou, T., Li, Y., Cheng, X., Chen, Z., Chen, J., & Zheng, W. V. (2023). Bispecific GPC3/PD‑1 CAR‑T cells for the treatment of HCC. International Journal of Oncology, 62(4). https://doi.org/10.3892/ijo.2023.5501
Vancouver
Li D, Qin J, Zhou T, Li Y, Cheng X, Chen Z, et al. Bispecific GPC3/PD‑1 CAR‑T cells for the treatment of HCC. International Journal of Oncology. 2023;62(4). doi:10.3892/ijo.2023.5501
BibTeX
@article{Li2023,
author = {Li, Dezhi and Qin, Jie and Zhou, Tao and Li, Yaqin and Cheng, Xianyi and Chen, Zaizhong and Chen, Junhui and Zheng, Wei V},
title = {Bispecific GPC3/PD‑1 CAR‑T cells for the treatment of HCC},
journal = {International Journal of Oncology},
year = {2023},
volume = {62},
number = {4},
doi = {10.3892/ijo.2023.5501}
}
EUVIMED